Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Product comparison
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Product comparison

2 evidence topics · 8 sources

Systematic review: included studies and overall survival data

“5 studies comprising 1,365 patients were included.” (opens the source at this quote in a new tab)
“as OS data were largely immature or unreported in the included studies” (opens the source at this quote in a new tab)

Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure

“Eleven RCTs (n=3,606) were analyzed.” (opens the source at this quote in a new tab)